Receptor binding domain-IgG levels correlate with protection in residents facing SARS-CoV-2 B.1.1.7 outbreaks.
Hubert BlainEdouard TuaillonLucie GamonAmandine PisoniStéphanie MiotValentin DelpuiNejm Si-MohamedClémence NielYves RollandBrigitte MontesSoraya GrocSophia RafasseAnne-Marie DupuyNathalie GrosDelphine MuriauxMarie-Christine PicotJean BousquetPublished in: Allergy (2021)
Two BNT162b2 doses are associated with a 48% reduction of SARS-CoV-2 incidence and a 91.3% reduction of death risk in residents from NHs facing a VOC-α outbreak. Post-vaccine RBD-IgG levels correlate with BNT162b2 protection against SARS-CoV-2 B.1.1.7.